StonvexLoading…
StonvexStonvexStonvexCore line items from ASML's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | €32.67B | €28.26B | €27.56B | €21.17B |
Operating Income | €11.30B | €9.02B | €9.04B | €6.50B |
Net Income | €9.61B | €7.57B | €7.84B | €5.62B |
EPS (Diluted) | €24.71 | €19.24 | €19.89 | €14.13 |
Total Assets | €50.57B | €48.59B | €39.96B | €36.30B |
Total Liabilities | €30.95B | €30.11B | €26.51B | €27.49B |
Cash & Equivalents | €12.92B | €12.74B | €7.00B | €7.27B |
Free Cash Flow OCF − CapEx | €11.08B | €9.10B | €3.29B | €7.21B |
Shares Outstanding | 385.42M | 393.28M | 393.42M | 394.59M |